Patents by Inventor Ian McCaffery
Ian McCaffery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210221905Abstract: Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same. The antibodies provided include amino acid substitution embodiments affecting the antibody glycosylation state. The antibodies provided herein are, inter alia, useful for the treatment of cancer and effective for inhibition of CD73 activity.Type: ApplicationFiled: August 27, 2020Publication date: July 22, 2021Inventors: Emily Piccione Griffin, Richard A. Miller, Ian McCaffery
-
Patent number: 11040040Abstract: Provided herein are, inter alia, methods of treating a cancer tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an adenosine A2A receptor antagonist, wherein the subject comprises an elevated level of CD8+ tumor infiltrating lymphocytes relative to a control, the subject comprises an elevated level of T-effector gene signature relative to a control, the subject comprises an increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, the cancer tumor comprises an elevated level of PD-L1 relative to a control, and/or the cancer tumor or the blood of the subject comprises an elevated level of CD73 relative to a control. Further provided are, inter alia, methods for determining whether a subject is likely to, is, or has responded to anti-cancer therapy comprising an A2A receptor antagonist.Type: GrantFiled: April 4, 2018Date of Patent: June 22, 2021Assignee: Corvus Pharmaceuticals, Inc.Inventors: Andrew Hotson, Richard A. Miller, Ian Mccaffery, Stephen Willingham
-
Publication number: 20210154199Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist or a combination of an adenosine-A2A (A2A) receptor antagonist and a programmed cell death protein 1 (PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.Type: ApplicationFiled: December 17, 2020Publication date: May 27, 2021Inventors: Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian Mccaffery, Andrew Hotson
-
Publication number: 20210107989Abstract: Provided herein are, inter alia, 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer in a subject expressing elevated levels of CD73.Type: ApplicationFiled: April 4, 2018Publication date: April 15, 2021Inventors: Emily Piccione GRIFFIN, Ian MCCAFFERY
-
Patent number: 10912776Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.Type: GrantFiled: December 22, 2016Date of Patent: February 9, 2021Assignee: CORVUS PHARMACEUTICALS, INC.Inventors: Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian McCaffery, Andrew Hotson
-
Publication number: 20210008206Abstract: Provided herein are, inter alia, methods for treating cancer in subjects expressing elevated levels of adenosine A2A receptors, and optionally further expressing elevated levels of CD73 and/or PD-L1, by administering adenosine pathway inhibitors.Type: ApplicationFiled: November 6, 2018Publication date: January 14, 2021Inventors: Richard A. Miller, Ian Mccaffery, Andrew Hotson
-
Patent number: 10793636Abstract: Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same. The antibodies provided include amino acid substitution embodiments affecting the antibody glycosylation state. The antibodies provided herein are, inter alia, useful for the treatment of cancer and effective for inhibition of CD73 activity.Type: GrantFiled: July 11, 2017Date of Patent: October 6, 2020Assignee: CORVUS PHARMACEUTICALS, INC.Inventors: Emily Piccione Griffin, Richard A. Miller, Ian McCaffery
-
Publication number: 20200297728Abstract: Provided herein are, inter alia, methods of treating a cancer tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an adenosine A2A receptor antagonist, wherein the subject comprises an elevated level of CD8+ tumor infiltrating lymphocytes relative to a control, the subject comprises an elevated level of T-effector gene signature relative to a control, the subject comprises an increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, the cancer tumor comprises an elevated level of PD-L1 relative to a control, and/or the cancer tumor or the blood of the subject comprises an elevated level of CD73 relative to a control. Further provided are, inter alia, methods for determining whether a subject is likely to, is, or has responded to anti-cancer therapy comprising an A2A receptor antagonist.Type: ApplicationFiled: April 4, 2018Publication date: September 24, 2020Inventors: Andrew Hotson, Richard A. Miller, Ian Mccaffery, Stephen Willingham
-
Publication number: 20200261462Abstract: Provided herein are, inter alia, methods for treating cancer in subjects expressing elevated levels of adenosine A2A receptors, and optionally further expressing elevated levels of CD73 and/or PD-L1, by administering adenosine pathway inhibitors and PD-1 pathway inhibitors.Type: ApplicationFiled: November 6, 2018Publication date: August 20, 2020Inventors: Richard A. Miller, Ian Mccaffery, Andrew Hotson
-
Publication number: 20190076433Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2Areceptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.Type: ApplicationFiled: December 22, 2016Publication date: March 14, 2019Inventors: Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian McCaffery, Andrew Hotson
-
Publication number: 20190022096Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist, or a combination of an adenosine-A2A (A2A) receptor antagonist, CTLA4 antagonist a programmed cell death protein 1 (PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a CTLA4 antagonist and a PD-1 signaling pathway inhibitor, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: April 4, 2018Publication date: January 24, 2019Inventors: Stephen Willingham, Ian McCaffery
-
Patent number: 8865413Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.Type: GrantFiled: May 4, 2011Date of Patent: October 21, 2014Assignee: Celera CorporationInventors: Bruno Domon, Ian McCaffery, Vaibhav Narayan, Scott Patterson
-
Publication number: 20140037642Abstract: The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions, and kits for practicing the foregoing.Type: ApplicationFiled: February 2, 2012Publication date: February 6, 2014Applicant: AMGEN INC.Inventors: Ian McCaffery, Jian-Feng Lu
-
Publication number: 20130067608Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: August 16, 2012Publication date: March 14, 2013Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Aiqun LI, Tao HE, Ian MCCAFFERY
-
Publication number: 20120128677Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.Type: ApplicationFiled: May 4, 2011Publication date: May 24, 2012Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Ian MCCAFFERY, Vaibhav NARAYAN, Scott PATTERSON
-
Publication number: 20110296544Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: May 16, 2011Publication date: December 1, 2011Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Alqun Li, Tao He, Ian McCaffery
-
Patent number: 7960100Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: GrantFiled: March 17, 2008Date of Patent: June 14, 2011Assignee: Celera CorporationInventors: Bruno Domon, Aiqun Li, Tao He, Ian McCaffery
-
Patent number: 7776555Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: GrantFiled: July 2, 2007Date of Patent: August 17, 2010Assignee: Celera CorporationInventors: Bruno Domon, Steve Ruben, Charles E. Birse, Yeoun Jin Kim, Tao He, Ian McCaffery
-
Publication number: 20090138977Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.Type: ApplicationFiled: October 3, 2008Publication date: May 28, 2009Applicant: CELERA CORPORATIONInventors: Bruno Domon, Ian McCaffery, Vaibhav Narayan, Scott Patterson
-
Patent number: 7473531Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.Type: GrantFiled: August 6, 2004Date of Patent: January 6, 2009Assignee: Colora CorporationInventors: Bruno Domon, Ian McCaffery, Vaibhav Narayan, Scott Patterson